Biologics and biosimilars litigation update

Catch up on the third and final webinar in our 2020 series on decisions in the United States and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 3 focuses on recent key developments in the United States and Europe, including:

• Recent decisions and developments in the United States which may impact biologics and biosimilars, including Arthrex v Smith & Nephew, AAM v Becerra, and GSK v Teva.
• Recent decisions and developments in Europe, including the Santen CJEU decision, enforcement of personalised medicine claims, and the UK’s guidelines for biosimilars post Brexit.